Lost password ?
<< Back to Equity Research
Gulf Pharmaceutical
JULPHAR, NEEDS TO LUSTER ITS TARNISHED IMAGE
Jul 17 - With a YTD return of -19%, Gulf Pharmaceutical (Sell, UAE) has been the second worst performer within the AlphaMena’s small pharma universe behind JPM (Buy, Jordan). The biggest capitalisation ...
Executive summary
Conflict of Interest
Pages 40
Language English
Publish on July 17, 2019
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 15 PM
Idea Kicker
JULPHAR, WAITING FOR A SAFETY MARGIN
Mar 19 AM
Gulf Pharmaceutical
A better Q4 lifted our Target Price
Mar 16 PM
Gulf Pharmaceutical
A hit from outside GCC revenues in 2023
Mar 04 PM
Gulf Pharmaceutical
Modest 2023 results despite a better-than-expected Q4
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ